Compare Procter & Gamble Co (PG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Sanofi SA — how do they compare? Procter & Gamble Co trades at $150.91 (market cap $349.77B), while Sanofi SA trades at $40.16 (market cap $95.18B). The key difference: Procter & Gamble Co is far larger — about 3.7× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Procter & Gamble Co for 131 Days and Sanofi SA for 94 Days on average.
| PG | SNY | |
|---|---|---|
Market Cap | $349.77B | $95.18B |
Volume | 10,055,825 | 2,995,646 |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $52.34 |
52-Week Low | $138.10 | $39.51 |
Typical Hold Time | 131 Days | 94 Days |
Enterprise Value | $375.61B | $114.48B |
Dividend Yield | 2.89% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $150.87, up 2.06% today, showing strong momentum near its consensus price target of $160.13. The stock maintains a bullish technical outlook with moving averages supporting upward momentum, while fundamentals reveal consistent earnings beats and robust profitability with 18.44% net margins. Recent corporate developments include a new WNBA partnership and a $1.09 dividend declaration, reinforcing its stable income appeal.
PG offers reliable growth with three consecutive earnings beats and strong cash flow generation, though premium valuation multiples pose near-term risk. The company's supply chain enhancements and dividend track record provide stability, but investors face headwinds from soft demand concerns and elevated P/E ratios. Wall Street maintains a bullish stance with 53% buy ratings, suggesting moderate upside potential.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
